publication venue for
- Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition.. 3. 2011
- Safety and stability of retrovirally transduced chimeric antigen receptor T cells. 2012
- Research highlights: Immunotherapy. 2009
- Immunotherapies in transplantation and cancer: 22nd NAT meeting/2nd NAT LabEx IGO joint meeting; 1-2 June 2017, Nantes, France. 2017
- Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer.. 11. 2019
- A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.. 8. 2016
- Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies.. 5. 2013
- Atherosclerosis: immunopathogenesis and strategies for immunotherapy. 2021
- Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. 2021
- Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. 2019
- Fostamatinib for persistent/chronic adult immune thrombocytopenia. 2017
- Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. 2017
- Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. 2016
- Current status of engineered T-cell therapy for synovial sarcoma. 2016
- Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. 2016
- Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. 2016
- Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. 2015
- Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. 2015
- CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? 2015
- Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. 2013
- Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. 2011
- Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. 2010
- Update on intravesical agents for non-muscle-invasive bladder cancer. 2010